---
type: citation-audit
section: 1
pipeline_stage: "Stage 17 fix re-verification"
run_date: 2026-07-25
auditor: evidence-citation-agent (independent re-verification thread)
status: FAIL — 1 of 3 known fixes does not hold as literally cited (broken/missing file target); 2 of 3 confirmed genuinely fixed; no new prose-level defects found in broader spot check
---

# Stage 17 Fix Re-Verification — Section 1 (Executive Summary)

Independent, fresh-eyes re-check of the 3 defects reported fixed 2026-07-25 in
`Citation_Audit_WholePlan_Stage17_Sections01-02.md` / `..._Section13.md`, plus a broader spot check of
Section 1's cross-section citations. No prior report's conclusions were trusted; every source file was
opened directly.

## Fix 1 — GMV "USD 9.5 billion, FY2025" retargeted to `Problem_Charter.md`

**HOLDS.** `Problem_Charter.md` §"Strategic problem" states verbatim: *"FY2025 GMV of USD 9.5 billion
(+28% cFX)."* Section 1 cites `Problem_Charter.md` for this figure in three places — the Situation
paragraph (line 91), the "Business Name and Overview" section (line 202-203), and the traceability
table row "GMV of USD 9.5 billion, FY2025 | `Problem_Charter.md`" (line 264) — all three consistent with
each other and with the source. No remaining reference to `Section_02_Business_Description.md` §2.1 for
this figure.

## Fix 2 — "6.0% in Q4 2025" EBITDA-margin comparator now cited to Section 9 §9.3-9.4 and Section 3 §3.3

**HOLDS.** Both cited targets state the figure:
- `Section_09_Financial_Plan.md` §9.3 (line 24): "Adjusted EBITDA of 4.4-4.8% of GMV (down from 6.0% in
  Q4 2025)"; §9.4 (line 77): "Adjusted EBITDA margin moving from 6.0% (Q4 2025 actual) to a realized
  4.8% (Q1 2026 actual)..."
- `Section_03_Market_Analysis.md` §3.3 (lines 264-266, SWOT Threats): "Group Adjusted EBITDA margin
  compression is already realized... 6.0% (Q4 2025 baseline) stepping down to a 4.4-4.8% FY2026 guided
  range, with 4.8% already the actual Q1 2026 result."

Section 1's prose (Complication section) and traceability table row both now carry this citation
consistently.

## Fix 3 — Churn claim narrowed to "Group level or for Egypt specifically," matching Section 13

**DOES NOT HOLD AS CITED — the cited file does not exist on disk under its stated name.**

The prose fix itself is genuine and correct in substance: Section 1 now reads "no churn rate,
definition, or baseline exists anywhere in the corpus, at Group level or for Egypt specifically" (line
189-191), matching Section 13's own current wording, "No churn rate, definition, or cohort analysis
exists anywhere in the corpus, for talabat overall (Group) or for Egypt specifically" — same scope,
same substance.

However, Section 1 cites this to `Section_13_Monitoring_and_Evaluation.md` (line 194, and traceability
row line 275), and **that file does not currently exist at that path.** `git status` at session start
shows it as deleted in the working tree (`D vault/Projects/Business_Plan_Drafts_v2/Section_13_Monitoring_
and_Evaluation.md`), and a `Read` on that exact path returns "File does not exist." The content that
matches Section 1's claim is only found in a different, untracked file:
`vault/Projects/Business_Plan_Drafts_v2/Section_13_Monitoring_and_Evaluation 2.md` (note the space and
"2" suffix — a stray duplicate, not the canonical filename). That file's own frontmatter self-reports a
"Repository incident, 2026-07-25: this file was found genuinely deleted from the repo... restored from
the last good commit" — but the restore evidently wrote the content to a wrongly-named duplicate rather
than to the canonical `Section_13_Monitoring_and_Evaluation.md` path, leaving the canonical path missing
today. Every citation in this plan (including Section 1's own three references to
`Section_13_Monitoring_and_Evaluation.md`, and its `[[Section link]]`-style wikilink conventions used
elsewhere) resolves against the canonical filename, which does not exist. This is a citation-audit
failure per the skill's own rule (a claim tracing "to nothing" — here, to a non-existent file target,
regardless of the correctness of the content once you know to look at the duplicate) — 0% tolerance
applies. **Fix needed:** restore/rename the content back to
`vault/Projects/Business_Plan_Drafts_v2/Section_13_Monitoring_and_Evaluation.md` (the canonical path)
and delete the stray "`... 2.md`" duplicate, then re-confirm no other section's citations to Section 13
are similarly broken.

## Traceability table cross-check (stage 3 of the task)

All three corresponding rows (lines 263, 264, 275) were updated consistently with the prose:
- Row "GMV of USD 9.5 billion, FY2025 | `Problem_Charter.md`" — consistent with Fix 1.
- Row "Q4 2025 Adjusted EBITDA margin 6.0% (comparator) | `Section_09_Financial_Plan.md` §9.3-9.4;
  `Section_03_Market_Analysis.md` §3.3" — consistent with Fix 2.
- Row "No churn rate/baseline anywhere in the corpus | `Section_13_Monitoring_and_Evaluation.md`,
  'Churn — the Single Biggest Customer-Side Gap'" — consistent with the Fix-3 prose wording, but
  inherits the same broken-file-target defect as the prose citation.

## Broader fresh check (10 additional cross-section claims spot-checked)

All 10 traced cleanly to their cited source and current text, no drift found:

1. "Multi-vertical...Everyday App" framing — `Section_02_Business_Description.md` §2.1 (line 61):
   confirmed, TLB-020 p.16.
2. USD175mn = ~120mn/~55mn split — Section 2 §2.1 (line 90) and traceability row: confirmed.
3. Governing hypothesis — Section 2 §2.3 exists (line 114), heading matches citation.
4. Grocery/retail 1-3% of USD104-150bn+ — `Section_03_Market_Analysis.md` §3.1 (lines 129-162, 250):
   confirmed, with the reconciliation caveat intact.
5. No internal capital-allocation stage-gate — `Section_08_Operations_Plan.md` §8.4 / general Systems
   finding (line 120): confirmed, "no internal capital-allocation committee, approval threshold, or
   stage-gate process."
6. Top three risks FIN-01/MKT-01/ORG-01, High×High quadrant — `Section_10_Risk_Analysis.md` §10.6
   (lines 305-321): confirmed verbatim.
7. talabat pro/adtech EBITDA contribution ">USD14mn FY2024 → >USD30mn FY2025" —
   `Section_05_AI_Technology_and_Development.md` (line 30): confirmed.
8. Human/team approval before capital moves — `Problem_Charter.md` + `Section_11_CSR_and_Responsible_
   AI.md` §11.3 (lines 235-243): confirmed, quotes the Charter verbatim.
9. DEC-009 near-term sequence (OPT-002/OPT-003 near-term, OPT-001/OPT-005 continue-at-pace, OPT-004
   longer-horizon) — `vault/Decisions/Decision_Log/DEC-009_investment-options-ranking-and-allocation-
   priority.md` (lines 156-157): confirmed, matches Section 1's Answer exactly. Note: DEC-009 lives at
   `vault/Decisions/Decision_Log/DEC-009_...md`, not a bare top-level filename — Section 1 references it
   only by ID (`DEC-009`), not a literal path, so this is not a citation defect, but flagged for
   awareness given the Section 13 path issue found above.
10. OPT-004 ~7%-of-GMV UAE advertising benchmark, longer-horizon framing —
    `Section_12_Implementation_Plan.md` (lines 37, 75-76, 121, 126): confirmed.

No other numeric or named-fact claim in Section 1 was found untraceable, stale, or geography-mismatched
in this pass. The Geographic Evidence Rules check (Group vs. GCC vs. non-GCC vs. Egypt labeling) was
applied to every figure re-checked above; all carry correct-level labels (e.g., "Group" tags on GMV/
EBITDA figures, UAE/Kuwait/Qatar-scoped tag on the M1 retention figure, Egypt-specific tag only where
the source itself is Egypt-specific).

## Overall verdict

Section 1 cannot proceed to Stage 17 sign-off / Stage 10 as fully clean: Fix 3's citation target is a
missing file at the time of this audit, a hard failure under the citation-audit skill's 0% tolerance
rule, independent of whether the underlying claim content is correct. Fixes 1 and 2 are confirmed
genuinely resolved. No new defects were found in the broader 10-claim spot check.
